Cystatin C and the Risk of Frailty and Mortality in Older Men

Allyson Hart, Terri L. Blackwell, Misti L. Paudel, Brent C. Taylor, Eric Orwoll, Peggy M. Cawthon, Kristine E. Ensrud

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: This study examines the association between cystatin C (cysC) levels and risks of progression of frailty status or death in older men. Methods: Prospective study of 2,613 men without overt frailty aged 67 years and older enrolled in the MrOS ancillary sleep study. Baseline measurements included serum cysC, serum creatinine, and frailty status. Repeat frailty status, performed an average of 3.4 years later, was assessed as an ordinal outcome of robust, intermediate stage (prefrail), frail or dead. Results: Mean age was 75.7 years. Men with higher cysC were older and had a higher comorbidity burden. After adjusting for age, clinical site, and race, higher cysC was associated with nearly twofold greater odds of being classified as intermediate stage versus robust (OR quartile 4 vs 1; 1.82, 95% confidence interval [CI] 1.35-2.45), a threefold greater odds of frailty versus robust (OR quartile 4 vs 1; 3.13, 95% CI 2.03-4.82), and a more than fivefold greater odds of death versus robust (OR quartile 4 vs 1; 5.48, 95% CI 2.98-10.08). Results were similar for cysC-based estimated glomerular filtration rate (eGFR). This relationship was attenuated but persisted after adjusting for additional potential confounders including baseline frailty status, body mass index, smoking status, comorbidity burden, self-reported disability, and serum albumin. In contrast, neither serum creatinine nor creatinine-based eGFR was associated in a graded manner with higher risks of development of frailty or death. Conclusions: In this cohort of older men without overt frailty, higher cysC and cysC-based eGFR, but not creatinine or creatinine-based estimates of GFR, were associated with increased risks of frailty or death. These findings suggest that higher cysC level may be a promising biomarker for unsuccessful aging as manifested by increased risks of frailty and death.

Original languageEnglish (US)
Pages (from-to)965-970
Number of pages6
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume72
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Cystatin C
Mortality
Creatinine
Glomerular Filtration Rate
Confidence Intervals
Comorbidity
Serum
Serum Albumin
Sleep
Body Mass Index
Biomarkers
Smoking
Prospective Studies

Keywords

  • Creatinine
  • Cystatin C
  • Frailty
  • Men
  • Mortality

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

Cystatin C and the Risk of Frailty and Mortality in Older Men. / Hart, Allyson; Blackwell, Terri L.; Paudel, Misti L.; Taylor, Brent C.; Orwoll, Eric; Cawthon, Peggy M.; Ensrud, Kristine E.

In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 72, No. 7, 01.07.2017, p. 965-970.

Research output: Contribution to journalArticle

Hart, Allyson ; Blackwell, Terri L. ; Paudel, Misti L. ; Taylor, Brent C. ; Orwoll, Eric ; Cawthon, Peggy M. ; Ensrud, Kristine E. / Cystatin C and the Risk of Frailty and Mortality in Older Men. In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2017 ; Vol. 72, No. 7. pp. 965-970.
@article{2b4b1f9dd7d340fabc624b124bf1ecd8,
title = "Cystatin C and the Risk of Frailty and Mortality in Older Men",
abstract = "Background: This study examines the association between cystatin C (cysC) levels and risks of progression of frailty status or death in older men. Methods: Prospective study of 2,613 men without overt frailty aged 67 years and older enrolled in the MrOS ancillary sleep study. Baseline measurements included serum cysC, serum creatinine, and frailty status. Repeat frailty status, performed an average of 3.4 years later, was assessed as an ordinal outcome of robust, intermediate stage (prefrail), frail or dead. Results: Mean age was 75.7 years. Men with higher cysC were older and had a higher comorbidity burden. After adjusting for age, clinical site, and race, higher cysC was associated with nearly twofold greater odds of being classified as intermediate stage versus robust (OR quartile 4 vs 1; 1.82, 95{\%} confidence interval [CI] 1.35-2.45), a threefold greater odds of frailty versus robust (OR quartile 4 vs 1; 3.13, 95{\%} CI 2.03-4.82), and a more than fivefold greater odds of death versus robust (OR quartile 4 vs 1; 5.48, 95{\%} CI 2.98-10.08). Results were similar for cysC-based estimated glomerular filtration rate (eGFR). This relationship was attenuated but persisted after adjusting for additional potential confounders including baseline frailty status, body mass index, smoking status, comorbidity burden, self-reported disability, and serum albumin. In contrast, neither serum creatinine nor creatinine-based eGFR was associated in a graded manner with higher risks of development of frailty or death. Conclusions: In this cohort of older men without overt frailty, higher cysC and cysC-based eGFR, but not creatinine or creatinine-based estimates of GFR, were associated with increased risks of frailty or death. These findings suggest that higher cysC level may be a promising biomarker for unsuccessful aging as manifested by increased risks of frailty and death.",
keywords = "Creatinine, Cystatin C, Frailty, Men, Mortality",
author = "Allyson Hart and Blackwell, {Terri L.} and Paudel, {Misti L.} and Taylor, {Brent C.} and Eric Orwoll and Cawthon, {Peggy M.} and Ensrud, {Kristine E.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1093/gerona/glw223",
language = "English (US)",
volume = "72",
pages = "965--970",
journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",
issn = "1079-5006",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Cystatin C and the Risk of Frailty and Mortality in Older Men

AU - Hart, Allyson

AU - Blackwell, Terri L.

AU - Paudel, Misti L.

AU - Taylor, Brent C.

AU - Orwoll, Eric

AU - Cawthon, Peggy M.

AU - Ensrud, Kristine E.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background: This study examines the association between cystatin C (cysC) levels and risks of progression of frailty status or death in older men. Methods: Prospective study of 2,613 men without overt frailty aged 67 years and older enrolled in the MrOS ancillary sleep study. Baseline measurements included serum cysC, serum creatinine, and frailty status. Repeat frailty status, performed an average of 3.4 years later, was assessed as an ordinal outcome of robust, intermediate stage (prefrail), frail or dead. Results: Mean age was 75.7 years. Men with higher cysC were older and had a higher comorbidity burden. After adjusting for age, clinical site, and race, higher cysC was associated with nearly twofold greater odds of being classified as intermediate stage versus robust (OR quartile 4 vs 1; 1.82, 95% confidence interval [CI] 1.35-2.45), a threefold greater odds of frailty versus robust (OR quartile 4 vs 1; 3.13, 95% CI 2.03-4.82), and a more than fivefold greater odds of death versus robust (OR quartile 4 vs 1; 5.48, 95% CI 2.98-10.08). Results were similar for cysC-based estimated glomerular filtration rate (eGFR). This relationship was attenuated but persisted after adjusting for additional potential confounders including baseline frailty status, body mass index, smoking status, comorbidity burden, self-reported disability, and serum albumin. In contrast, neither serum creatinine nor creatinine-based eGFR was associated in a graded manner with higher risks of development of frailty or death. Conclusions: In this cohort of older men without overt frailty, higher cysC and cysC-based eGFR, but not creatinine or creatinine-based estimates of GFR, were associated with increased risks of frailty or death. These findings suggest that higher cysC level may be a promising biomarker for unsuccessful aging as manifested by increased risks of frailty and death.

AB - Background: This study examines the association between cystatin C (cysC) levels and risks of progression of frailty status or death in older men. Methods: Prospective study of 2,613 men without overt frailty aged 67 years and older enrolled in the MrOS ancillary sleep study. Baseline measurements included serum cysC, serum creatinine, and frailty status. Repeat frailty status, performed an average of 3.4 years later, was assessed as an ordinal outcome of robust, intermediate stage (prefrail), frail or dead. Results: Mean age was 75.7 years. Men with higher cysC were older and had a higher comorbidity burden. After adjusting for age, clinical site, and race, higher cysC was associated with nearly twofold greater odds of being classified as intermediate stage versus robust (OR quartile 4 vs 1; 1.82, 95% confidence interval [CI] 1.35-2.45), a threefold greater odds of frailty versus robust (OR quartile 4 vs 1; 3.13, 95% CI 2.03-4.82), and a more than fivefold greater odds of death versus robust (OR quartile 4 vs 1; 5.48, 95% CI 2.98-10.08). Results were similar for cysC-based estimated glomerular filtration rate (eGFR). This relationship was attenuated but persisted after adjusting for additional potential confounders including baseline frailty status, body mass index, smoking status, comorbidity burden, self-reported disability, and serum albumin. In contrast, neither serum creatinine nor creatinine-based eGFR was associated in a graded manner with higher risks of development of frailty or death. Conclusions: In this cohort of older men without overt frailty, higher cysC and cysC-based eGFR, but not creatinine or creatinine-based estimates of GFR, were associated with increased risks of frailty or death. These findings suggest that higher cysC level may be a promising biomarker for unsuccessful aging as manifested by increased risks of frailty and death.

KW - Creatinine

KW - Cystatin C

KW - Frailty

KW - Men

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85021780545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021780545&partnerID=8YFLogxK

U2 - 10.1093/gerona/glw223

DO - 10.1093/gerona/glw223

M3 - Article

C2 - 28329858

AN - SCOPUS:85021780545

VL - 72

SP - 965

EP - 970

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

SN - 1079-5006

IS - 7

ER -